FEM1A

FEM1A is a substrate receptor subunit of CUL2-RING E3 ubiquitin ligase complexes (CRL2^FEM1A) that recognizes arginine C-terminal degrons (Arg/C-degrons) on substrate proteins through its ankyrin repeat domain, directing their ubiquitin-mediated proteasomal degradation (PMID:33398168). FEM1A, together with FEM1B and FEM1C, mediates the proteasomal degradation of Stem-Loop Binding Protein (SLBP) by recognizing a distinct N-terminal degron, contributing to cell-cycle-regulated SLBP turnover in an evolutionarily conserved pathway (PMID:28118078). In muscle cells, FEM1A localizes to mitochondria, interacts with the EP4 prostaglandin receptor, and is upregulated following myocardial ischemia-reperfusion injury and during myocyte terminal differentiation (PMID:19406122, PMID:16254458).

1. 1998 Medium

   Cloning of mouse Fem1a established that vertebrates possess a homolog of C. elegans sex-determination factor FEM-1 containing seven ankyrin repeat domains, with preferential expression in heart and skeletal muscle, raising the question of whether it functions in cell-fate determination outside nematode sex determination.

   Evidence Gene cloning, sequence analysis, and Northern blot in mouse tissues

   PMID:9828124

   Open questions at the time

   • No biochemical activity or binding partners identified
   • Functional role in muscle beyond expression pattern unknown
   • Relationship to ubiquitin-proteasome system not yet recognized
2. 2001 Low

   Characterization of the human FEM1A ortholog confirmed conservation of ankyrin repeat architecture and tissue expression (kidney, heart), establishing the gene's identity and genomic position but leaving its molecular function unknown.

   Evidence cDNA cloning, FISH chromosomal mapping, Northern blot in human tissues

   PMID:11733146

   Open questions at the time

   • No direct biochemical or functional assay performed
   • No interacting partners identified
   • Mechanism of action entirely uncharacterized
3. 2005 Low

   FEM1A expression was found to be activated specifically during terminal myocyte differentiation and consistently downregulated in rhabdomyosarcoma, linking it to myogenic cell-fate determination and suggesting a tumor-suppressive context.

   Evidence RT-PCR/Northern blot during C2C12 differentiation, expression analysis in human RMS lines and multiple mouse genetic RMS models

   PMID:16254458

   Open questions at the time

   • Correlative expression data only — no functional rescue or knockdown phenotype
   • Molecular targets and pathway placement undefined
   • Causality between FEM1A loss and tumorigenesis not tested
4. 2009 Medium

   Subcellular localization of FEM1A to mitochondria in muscle cells and identification of the EP4 prostaglandin receptor as a binding partner provided the first spatial and interactome context, and upregulation after myocardial infarction suggested a stress-responsive role.

   Evidence Immunofluorescence, electron microscopy, biochemical fractionation in C2C12 myoblasts and cardiac cells; ischemia-reperfusion mouse model

   PMID:19406122

   Open questions at the time

   • Functional consequence of EP4 interaction unknown
   • Whether mitochondrial localization is linked to ubiquitin ligase function unclear
   • Mechanism of upregulation after ischemia not addressed
5. 2017 High

   Identification of SLBP as a direct degradation substrate of FEM1A (and FEM1B/C) via a distinct N-terminal degron established FEM1A as a ubiquitin-proteasome pathway component controlling cell-cycle-dependent histone mRNA metabolism, with evolutionary conservation from C. elegans to mammals.

   Evidence Co-immunoprecipitation, degron mutant analysis, cell-cycle expression profiling, C. elegans RNAi epistasis with CDL-1 readout

   PMID:28118078

   Open questions at the time

   • Full substrate repertoire beyond SLBP not defined
   • Whether FEM1A recognizes SLBP via an Arg/C-degron or a different motif class not resolved
   • Relative contributions of FEM1A vs. FEM1B/C to SLBP turnover not quantified
6. 2021 High

   Crystal structures of FEM1A bound to Arg/C-degron substrates revealed the structural basis of substrate recognition and demonstrated that FEM1A and FEM1C select distinct Arg/C-degron classes compared to FEM1B, establishing the molecular logic of degron selectivity within the FEM1 family.

   Evidence X-ray crystallography of FEM1A–degron complexes, in vitro binding assays, GPS analysis, mutagenesis

   PMID:33398168

   Open questions at the time

   • Physiological substrates recognized via Arg/C-degrons in vivo not comprehensively catalogued
   • How degron selectivity among FEM1A/B/C is regulated in different tissues remains unclear
   • No structural information on FEM1A in complex with CUL2–RBX1 scaffold

• It remains unknown how FEM1A's mitochondrial localization in muscle cells relates to its CRL2 substrate receptor function, what the full in vivo substrate repertoire is, and whether FEM1A loss causally contributes to muscle disease or rhabdomyosarcoma.
• No in vivo knockout phenotype reported
• Mitochondrial vs. cytosolic CRL2 activity not reconciled
• No disease-causative mutations identified